CHICAGO--(BUSINESS WIRE)--SIOGEN Biotech (Kuala Lumpur, Malaysia), an innovative leader in the field of silicon-based nanoparticle drug delivery and targeting, and Veeda Clinical Research (Ahmedabad, India), a global clinical research organisation, signed today at the BIO conference in Chicago a strategic partnership agreement to develop a new nanoparticle formulation of Doxorubicin to treat cancer.
